StockNews.AI
PRAX
StockNews.AI
133 days

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

1. Praxis is hosting a virtual investor event on May 2, 2025. 2. The event will discuss clinical programs in developmental and epileptic encephalopathies. 3. Focus includes studies on relutrigine and elsunersen for specific DEEs. 4. Praxis has a diversified CNS portfolio with multiple clinical-stage candidates.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming investor event could increase investor interest and confidence. Previous similar events have correlated with positive stock reactions.

How important is it?

Investor presentations can lead to increased market visibility and stock interest. The focus on clinical studies aligns with PRAX's core operations.

Why Short Term?

The event is imminent, likely affecting stock price in the days following. Similar past events have shown immediate market reactions.

Related Companies

AMGNVRTXNVS
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT. The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies (DEEs) including: The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEsThe EMERALD study evaluating relutrigine for broader DEEsThe EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE To RSVP and attend the live event, you may click here.   A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Related News